Institute of Basic Medical Sciences Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
Clin Exp Immunol. 2011 Apr;164(1):57-65. doi: 10.1111/j.1365-2249.2011.04321.x. Epub 2011 Mar 1.
Human peripheral blood monocytes are a heterogeneous population, including CD14(+) CD16(-) 'classical' monocytes and CD14(+) CD16(+) 'proinflammatory' monocytes. CD16(+) monocytes are expanded in various inflammatory conditions. However, little is known about the CD14(+) CD16(+) monocytes in patients with breast cancer. We detected CD14(+) CD16(+) monocytes in 96 patients with breast cancer and 54 control subjects using flow cytometry. Receiver-operating characteristic (ROC) curve analysis was used to determine the feasibility of CD14(+) CD16(+) monocytes as an indicator for diagnosis of breast cancer. We found that the frequency of CD14(+) CD16(+) monocytes showed a significantly greater increase in breast cancer patients than in controls (16·96% versus 10·84%, P < 0·0001). The area under the ROC curve for CD14(+) CD16(+) monocytes was 0·805 [95% confidence interval (95% CI): 0·714-0·877, P = 0·0001]. Furthermore, the levels of CD16(+) monocytes were significantly negatively associated with the tumour size and pathological staging. In vitro, we showed that CD14(+) CD16(+) monocytes were expanded significantly when the purified CD14(+) monocytes were exposed to Michigan Cancer Foundation (MCF)-7 cells-conditioned medium (MCF-CM) or, separately, to monocyte chemotactic protein 1 (MCP-1). Neutralizing antibodies against MCP-1 inhibited the expansion of CD14(+) CD16(+) monocytes by MCF-CM. Collectively, our findings indicated that MCP-1 can expand CD14(+) CD16(+) monocytes in patients with breast cancer. Furthermore, the CD14(+) CD16(+) monocyte may be a useful indicator in early diagnosis of breast cancer.
人外周血单核细胞是一个异质群体，包括 CD14(+) CD16(-)“经典”单核细胞和 CD14(+) CD16(+)“促炎”单核细胞。CD16(+)单核细胞在各种炎症情况下扩增。然而，关于乳腺癌患者的 CD14(+) CD16(+)单核细胞知之甚少。我们使用流式细胞术检测了 96 例乳腺癌患者和 54 例对照者的 CD14(+) CD16(+)单核细胞。接收者操作特性（ROC）曲线分析用于确定 CD14(+) CD16(+)单核细胞作为乳腺癌诊断指标的可行性。我们发现，乳腺癌患者 CD14(+) CD16(+)单核细胞的频率明显高于对照组（16.96%比 10.84%，P<0.0001）。CD14(+) CD16(+)单核细胞的 ROC 曲线下面积为 0.805[95%置信区间（95%CI）：0.714-0.877，P=0.0001]。此外，CD16(+)单核细胞的水平与肿瘤大小和病理分期呈显著负相关。在体外，我们表明当纯化的 CD14(+)单核细胞暴露于密歇根癌症基金会（MCF）-7 细胞条件培养基（MCF-CM）或单独暴露于单核细胞趋化蛋白 1（MCP-1）时，CD14(+) CD16(+)单核细胞明显扩增。MCP-1 中和抗体抑制 MCF-CM 扩增 CD14(+) CD16(+)单核细胞。总的来说，我们的研究结果表明，MCP-1 可以扩增乳腺癌患者的 CD14(+) CD16(+)单核细胞。此外，CD14(+) CD16(+)单核细胞可能是乳腺癌早期诊断的有用指标。
